Clinical trials
1 active trial in France
Recruiting, about to start, or running now.
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment NCT07213323
Updated
Reviewed by Vidhi Upadhyay
France GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$4.06 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.18 Bn | — | — |
| 2025 (base) | $1.38 Bn | +$194.8 Mn | — |
| 2026 (forecast) | $1.60 Bn | +$226.9 Mn | +16.5% |
| 2027 (forecast) | $1.87 Bn | +$264.3 Mn | +35.7% |
| 2028 (forecast) | $2.17 Bn | +$308.0 Mn | +58.1% |
| 2029 (forecast) | $2.53 Bn | +$358.8 Mn | +84.2% |
| 2030 (forecast) | $2.95 Bn | +$418.0 Mn | +114.6% |
| 2031 (forecast) | $3.44 Bn | +$486.9 Mn | +150% |
| 2032 (forecast) | $4.01 Bn | +$567.3 Mn | +191.3% |
| 2033 (forecast) | $4.67 Bn | +$660.9 Mn | +239.3% |
| 2034 (forecast) | $5.44 Bn | +$769.9 Mn | +295.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.38 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $5.44 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 16.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, route of administration, application and end user (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and 1 more (see all) |
| Regulator in France | ANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026. |
| Active clinical trials | 1 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.
Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.
The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.[2] ClinicalTrials.gov lists 1 study on GLP-1 Receptor Agonists that is recruiting, active or about to start in France.[3] Obesity (adults): 11.2% of adults in 2024, the latest WHO figure for France.[4]
[1] ANSM, French medicines agency. Checked 14 Nov 2026.
[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.
What doctors and scientists are doing in GLP-1 Receptor Agonists right now, from free public sources.
1 active trial in France
Recruiting, about to start, or running now.
11.2 % of adults
Obesity (adults), France, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
France · 3 shared keywords
France · 3 shared keywords
France · 2 shared keywords
France · 2 shared keywords
France · 2 shared keywords
France · 2 shared keywords
Medical Devices · France
Medical Devices · France
Medical Devices · France
Medical Devices · France
Healthcare Services · France
Digital Health · France